Bin Yang
38Patents
7h-index
83Co-inventors
72Inventor score
Filing activity: Apr 8, 2002 → Jul 29, 2024
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6653443B2 | Multimerization of HIV-1 Vif protein as a therapeutic target | Emerging Cross-Sectional Technologies | 47 | Expired |
| US9778155B2 | Methods for phenotyping of intact whole tissues | Physics | 45 | Active |
| US8729017B2 | Glucagon/GLP-1 receptor co-agonists | Physics | 24 | Active |
| US7875444B2 | Lignin blockers and uses thereof | Emerging Cross-Sectional Technologies | 18 | Expired |
| US8981047B2 | Glucagon antagonists | Human Necessities | 16 | Active |
| US8980830B2 | Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity | Human Necessities | 15 | Active |
| US7604967B2 | Lignin-blocking treatment of biomass and uses thereof | Emerging Cross-Sectional Technologies | 13 | Expired |
| US9778154B2 | Methods for phenotyping of intact whole tissues | Physics | 6 | Active |
| US11746120B2 | Stat degraders and uses thereof | Human Necessities | 3 | Active |
| US8461170B2 | Chemical compounds | Chemistry; Metallurgy | 3 | Active |
| US7981903B2 | 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer | Chemistry; Metallurgy | 2 | Active |
| US8580541B2 | Lignin blockers and uses thereof | Emerging Cross-Sectional Technologies | 2 | Active |
| US11485750B1 | STAT degraders and uses thereof | Human Necessities | 2 | Active |
| US9783592B2 | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity | Chemistry; Metallurgy | 2 | Active |
| US10131663B2 | Chemical compounds | Human Necessities | 1 | Active |
| US7226741B2 | Multimerization of HIV-1 Vif protein as a therapeutic target | Emerging Cross-Sectional Technologies | 1 | Expired |
| US7498138B2 | Multimerization of HIV-1 Vif protein as a therapeutic target | Emerging Cross-Sectional Technologies | 1 | Active |
| US8338573B2 | Crystal structure of CD147 extracellular region and use thereof | Emerging Cross-Sectional Technologies | 1 | Active |
| US10196665B2 | Cell culture medium and methods for enhancing recombinant antibody purity | Chemistry; Metallurgy | 1 | Active |
| US9309301B2 | Glucagon/GLP-1 receptor co-agonists | Physics | 1 | Active |
| US10568892B2 | Cycloartane tetracyclic triterpenoid compound, preparation method therefor and use thereof | Human Necessities | 0 | Active |
| US10131889B1 | Candida antarctica lipase B mutant, and methods for making and using the same | Chemistry; Metallurgy | 0 | Active |
| US12194004B2 | Nano-delivery carrier for targeted tumor administration and application thereof | Human Necessities | 0 | Active |
| US9127088B2 | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity | Chemistry; Metallurgy | 0 | Active |
| US10125135B2 | Chemical compounds | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.